News
contact us

    KCI BioTech (Suzhou) Inc.
    Tel:0512-69998806
    Ministry of Commerce:0512-69998806-8012
    BD:
    East and South China:Ms. Gu 15378638068
    North China, East China:Mr. Han 18914988667
    Central and Western regions: Ms. Xiang 15828112963
    Project Management Department:0512-69998806-8022
    Tumor business:0512-69998806-8058
    Non tumor business:0512-69998806-8026
    Pathogenic microorganism business:0512-69998806-8037
    Integrated Service Platform:0512-69998806-8022
    Address: Building A2, Xinyang Industrial Park, No. 8 Yanghua Road, Suzhou Industrial Park
Company news Your current location:Home > Company news >

Jiangsu KMQ Biotechnology Co., Ltd. was established to further layout

Author:KCI&KMQ ComeFrom:原创 Date:2020/5/22 16:04:19 
KCI was established in November 2014. It is an enterprise that provides one-stop pre-clinical pharmacodynamics comprehensive evaluation services. It takes the advanced non-tumor disease model pharmacodynamic evaluation test platform as its core competitiveness, and provided more than 200 domestic and foreign new drugs’R&D institutions with a series of internal professional R&D promotion services including the establishment of preclinical drug efficacy disease models, testing and drug efficacy. The diseases involved include cardiovascular diseases, autoimmune diseases, inflammatory diseases, and metabolic diseases. Diseases, urinary system diseases, neurological diseases, liver diseases, etc. It has undertaken nearly 20 domestic and foreign CFDA/FDA declarations. In recent years, in response to the rapidly developing market of translational medicine, the company has established a comprehensive imaging medicine experimental base and introduced advanced imaging equipment suitable for non-human primates and other large animals.


Based on the existing CRO business technology, KCI is also actively expanding and developing new disease models to meet market needs. After the establishment of Jiangsu KMQ, it will further focus on the development of non-human primate disease models, especially the research and development and outsourcing services in the field of non-human primate tumor disease models. Dr. Yongjie Zhuang, founder and CEO of KCI and KMQ, said: "The establishment of KMQ is an affirmation and support of our KCI years of hard work. The company will continue to build a platform with core competitiveness and assist emerging biopharmaceutical companies in product research and development with the best service.


 About KCI 


KCI Biotech (SUZHOU) Inc. (KCI) is a preclinical Contract Research Organization (CRO) providing specialty preclinical pharmacology services in cardiovascular diseases, immune diseases, inflammatory diseases, metabolic diseases, urinary diseases, neuron diseases and oncology by using small and large animal disease models.


KCI locates in Nano Polis Suzhou industry park besides Jinji lake. The office and laboratory area are 1800 square meters, including 800 square meters of SPF barrier system for rats and mice, and 600 square meters of functional laboratory. It can carry out pharmacology and pharmacodynamics of 7000 mice and 5000 rats at the same time.   

Previous:Nothing
Next:Yan Miao, member of the Standing Committee of Yuxi Municipal Party Committee and director of the Organization Department of the Municipal Party Committee, and his group visited KCI company